Premium accounts now available! Sign up and create a premium account. Read more Close

Your cookie settings

This site uses cookies. Some cookies are essential to make the site work and others help us to improve our services. Read more about cookies in our Privacy policy.

Choose your cookie preferences:

Advertisement

Image

Shilpa Biocare invierte en la spin-off del IRB Barcelona Gate2Brain para impulsar un innovador candidato terapéutico para el cáncer cerebral

News - public release Created on 16 Jun 2026 Institute for Research in Biomedicine (IRB Barcelona)

Shilpa Biocare invests in Gate2Brain, an IRB Barcelona spin-off, to advance an innovative therapeutic candidate for brain cancer TanyaY Tue, 06/16/2026 - 09:17

Gate2Brain, a spin-off from IRB Barcelona, the University of Barcelona, and the Sant Joan de Déu research Institute devoted to the development of peptide-based delivery technologies for central nervous system diseases, has announced a strategic partnership with Shilpa Biocare Pvt Ltd, a wholly owned subsidiary of Shilpa Medicare Limited. 

TanyaY

Advertisement

Stats

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Do you recommend this? Please sign in. Yes No

Recommended

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement